| Line 29: | Line 29: | ||
==Pyoderma Gangrenosum== | ==Pyoderma Gangrenosum== | ||
==Sarcoidosis== | ==Sarcoidosis== | ||
===2013 [https://journal.chestnet.org/article/S0012-3692(13)60095-1/fulltext Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis]=== | |||
*The immune phenotype of patients with symptomatic [https://en.wikipedia.org/wiki/Sarcoidosis sarcoidosis] treated with nicotine closely resembled that of asymptomatic patients, supporting the notion that nicotine treatment may be beneficial in this patient population. | |||
*[https://www.researchgate.net/profile/Mark_Julian/publication/230645268_Nicotine_Treatment_Improves_TLR2_and_TLR9_Responsiveness_in_Active_Pulmonary_Sarcoidosis/links/556ca4af08aeab77722318be/Nicotine-Treatment-Improves-TLR2-and-TLR9-Responsiveness-in-Active-Pulmonary-Sarcoidosis.pdf PDF Version] | |||
*Citation: Mark W. Julian, MS; Guohong Shao, MD; Larry S. Schlesinger, MD; Qin Huang, MD; David G. Cosmar, BA; Nitin Y. Bhatt, MD; Daniel A. Culver, MD, FCCP; Robert P. Baughman, MD, FCCP; Karen L. Wood, MD, FCCP; and Elliott D. Crouser, MD - ORIGINAL RESEARCH DIFFUSE LUNG DISEASE| VOLUME 143, ISSUE 2, P461-470, FEBRUARY 01, 2013, DOI 10.1378/chest.12-0383 | |||
*Acknowledgements: This work was supported by the American Thoracic Society and the Foundation for Sarcoidosis Research. © 2013 American College of Chest Physicians | |||
==Seizures / Epilepsy== | ==Seizures / Epilepsy== | ||
edits